DDInter460 DDInter1435
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Cytarabine {u} (Compound) resembles {v} (Compound) Regadenoson
Cytarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Cytarabine {u} (Compound) binds {v} (Gene) POLB
Cytarabine {u} (Compound) upregulates {v} (Gene) TICAM1
Cytarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Cytarabine {u} (Compound) downregulates {v} (Gene) KIF4A
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Cytarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Cytarabine (Compound) resembles Regadenoson (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease)
Cytarabine (Compound) binds POLB (Gene)
Cytarabine (Compound) upregulates TICAM1 (Gene)
Cytarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Cytarabine (Compound) downregulates KIF4A (Gene)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin